Samidorphan L-Malate

CHEMBL2105749 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
504.5 g/mol
LogP
Phase
4

Samidorphan l-malate is the l-malate salt form of samidorphan, an opioid receptor antagonist used in combination with olanzapine for bipolar I disorder and major depressive disorder. See samidorphan for complete pharmacological details.

Moleküler Ağırlık

504,5000 g/mol

TPSA

199,00 Ų

Etki Mekanizması

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O

InChI

InChI=1S/C21H26N2O4.C4H6O5/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12;5-2(4(8)9)1-3(6)7/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26);2,5H,1H2,(H,6,7)(H,8,9)/t16-,20-,21-;2-/m10/s1

Molecular Formula

C25H32N2O9

HBD / HBA

6 / 10

Döndürülebilir Bağlar

6

Ağır Atomlar

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Samidorphan l-malate is the l-malate salt form of samidorphan, an opioid receptor antagonist used in combination with olanzapine for bipolar I disorder and major depressive disorder. See samidorphan for complete pharmacological details.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Samidorphan L-Malate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105749. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 53362094. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.